The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

22 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Pyrazole Inhibitors of GluN2B NMDA Receptor Subunit.EBI
Dart Neuroscience
Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.EBI
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.EBI
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.EBI
Merck Sharp & Dohme Research Laboratories
A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.EBI
Glaxosmithkline
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.EBI
University Of Strasburg
5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.EBI
Novartis Pharma
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.EBI
Astrazeneca Pharmaceuticals
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.EBI
Institut FüR Pharmazeutische Und Medizinische Chemie Der WestfäLischen Wilhelms-UniversitäT MüNster
Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor.EBI
Hamamatsu University School Of Medicine
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.EBI
Friedrich-Schiller-Universitat Jena
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.EBI
Merck Research Laboratories
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.EBI
Merck Research Laboratories
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.EBI
Merck Research Laboratories
Oxamides as novel NR2B selective NMDA receptor antagonists.EBI
Gedeon Richter
Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.EBI
Gedeon Richter
Orally efficacious NR2B-selective NMDA receptor antagonists.EBI
Merck Research Laboratories
3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.EBI
Merck Research Laboratories
Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.EBI
Parke-Davis Pharmaceutical Research
Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening.BDB
Waseda University
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.BDB
Bristol-Myers Squibb Pharmaceutical Research Institute
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.BDB
Astrazeneca